1207 - Testing for V600 status in patients with locally advanced or metastatic melanoma for access to appropriate therapies

Page last updated: 11 July 2016

Application Detail

Status

Closed

Description of Medical Service

BRAF V600 mutation testing for locally advanced unresectable stage III or IV melanoma to determine eligibility for access to dabrafenib (co-dependent technology).

Description of Medical Condition

Melanoma in its advanced form has a poor prognosis. It is increasing in incidence in Australia and globally, and occurs when mutations accumulate in the melanocytes of the skin, mainly as a result of exposure to ultra-violet radiation from sunlight. When mutations accumulate they can eventually deregulate growth and cell cycle control genes, and to lead to tumour formation through proliferation and metastasis of cells.

Reason for Application

-

Medical Service Type

-

Previous Application Number

Not Applicable

Associated Documentation

Application Form

-

PICO Confirmation

12-13 April 2012
Final Decision Analytic Protocol (PDF 2745 KB)
Final Decision Analytic Protocol (DAP) (Word 1022 KB)

Date of released for comment 27 January 2012
Consultation Decision Analytic Protocol (DAP) (PDF 826 KB)
Consultation Decison Analytic Protocol (DAP) (Word 751 KB)
Date of closed for comments 10 March 2012

Assessment Report

-

Public Summary Document

Public Summary Document - April 2013 (PDF 85 KB)
Public Summary Document - April 2013 (Word 678 KB)

Public Summary Document - August 2013 (PDF 80 KB)
Public Summary Document - August 2013 (Word 78 KB)

Meetings for this Application

PASC

1 to 2 December 2012
12 to 13 April 2012

ESC

13 to 14 June 2013

MSAC

5 April 2013
1 August 2013